J.D., University of Baltimore magna cum laude
M.S., Microbiology, Thomas Jefferson University
B.S., Biology, Villanova University
District of Columbia
United States Patent and Trademark Office
United States Court of Appeals for the Federal Circuit
American Bar Association
American Intellectual Property Law Association
Tech Council of Maryland/Maryland Bio
Butamax Advanced Biofuels, LLC
Mr. Jackman is a director in the Biotechnology/Chemical Group. His practice includes counseling clients in areas such as global patent portfolio procurement, management and enforcement strategies, FDA/ANDA practice, technology transfer, invalidity, noninfringement, freedom-to-operate and patentability opinions and due diligence investigations. He has significant experience in representing clients in patent reexaminations and inter partes review proceedings and has written and prosecuted patent applications domestically and internationally in areas such as immunology, genomics, molecular and cell biology, recombinant DNA technology, transgenics, bioprocessing, advanced biofuels, bio-based chemicals and enzymes, microbiology, therapeutic methods and food science.
Mr. Jackman is also a member of the firm's CleanTech Industry Group. He frequently lectures and publishes on intellectual property issues surrounding renewable technologies, and he was an Associate Editor for Clean Tech Law & Business, the first peer-reviewed journal devoted exclusively to the pursuit of environmentally sustainable technology.
Additionally, Mr. Jackman is a contributing author of Patent Office Litigation, Second Edition, published in 2017, the book provides a fresh and comprehensive exploration of patent office litigation proceedings, including how the proceedings interact with other aspects of patent procurement and enforcement, while delivering practical analysis and advice. This second edition of Patent Office Litigation is the follow up to the first version of the book that was published in 2012 by Thomson Reuters Westlaw that focused on the contested proceedings that were introduced under the America Invents Act that year.
Mr. Jackman previously served as a member of the MdBio Program Committee, a Division of the Tech Council of Maryland, which plans, organizes and facilitates educational seminars that provide a forum for members of the biotech and life science business community to learn and network with their peers. He further served as a member of the BIO International Convention Program Committee and the BIO World Congress on Industrial Biotechnology Program Committee.
During law school, Mr. Jackman served as Manuscripts Editor of the University of Baltimore Intellectual Property Law Journal and published an article on the "Adoption of a First-to-File Patent System: A Proposal" for the University of Baltimore Law Review. He received his J.D. with concentrations in both Intellectual Property Law and Business Law.
Mr. Jackman's thesis research concerned hepatitis B virus X antigen and its relation in the development of chronic liver diseases. As a graduate student, he co-authored a chapter entitled "Forensic Considerations in Environmental Pathology and Toxicology: Science, Regulation, Litigation, and a Tale of Two Toxins," in 2 FORENSIC SCIENCES 31F-1 (Cyril H. Wecht ed., 1995).
Prior to joining the firm, Mr. Jackman worked in the Office of Technology Development, National Cancer Institute, National Institutes of Health, as a Technology Transfer Fellow. He has also been an Adjunct Professor at the University of Baltimore School of Law co-teaching a course in Technology Transfer.
Unsolicited e-mails and information sent to Sterne, Kessler, Goldstein & Fox P.L.L.C. will not be considered confidential or privileged, may be disclosed to others, may not receive a response, and do not create an attorney-client relationship with Sterne Kessler. If you are not already a client of Sterne Kessler, do not include any confidential information in this message.